Compass is still being developed and is effectively in beta. Some content and features may be incomplete, change, or not work as expected.

Content is anchored to trusted sources where available, but Compass has not yet been clinically reviewed. It provides general information rather than medical advice.

Feedback helps us identify gaps, errors, usability problems and opportunities to improve Compass over time.

7 MND clinical trial updates to look out for in 2024

Original source

7 MND clinical trial updates to look out for in 2024Motor Neurone Disease Association (UK) · 25 January 2024

The fully recruited TUDCA-ALS trial was expected to report its first results in 2024. The trial is assessing the safety and efficacy of tauroursodeoxycholic acid (TUDCA) in motor neurone disease (MND).

Why this matters

These results could provide an initial indication of whether TUDCA is safe and shows signs of benefit in people with MND. They would not, on their own, establish whether it should be used as a treatment; full analysis and publication would still be needed.

Limitations and context

This is an update from the Motor Neurone Disease Association’s organisation blog, not a report of trial results. The source gives an expected reporting date, not confirmed findings. Top-line results are preliminary and require further analysis and publication.

Relevant to you?